Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ibi362
2. Ly3305677
1. Ibi362
2. Glxc-26803
3. 2259884-03-0
Molecular Weight | 4476 g/mol |
---|---|
Molecular Formula | C207H317N45O65 |
XLogP3 | -12.6 |
Hydrogen Bond Donor Count | 58 |
Hydrogen Bond Acceptor Count | 70 |
Rotatable Bond Count | 164 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 1750 |
Heavy Atom Count | 317 |
Formal Charge | 0 |
Complexity | 10500 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 31 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Details:
IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in patients with Type 2 Diabetes.
Lead Product(s): Mazdutide
Therapeutic Area: Endocrinology Brand Name: IBI362
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2024
Lead Product(s) : Mazdutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Innovent Announces NMPA Acceptance of Mazdutide NDA for Type 2 Diabetes
Details : IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in patients with Type 2 Diabetes.
Brand Name : IBI362
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 01, 2024
Details:
IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for chronic weight management.
Lead Product(s): Mazdutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: IBI362
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2024
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : Not Applicable
Deal Type : Not Applicable
Innovent bags another phase 3 win in China for next-gen Lilly GLP-1 drug
Details : IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for chronic weight management.
Brand Name : IBI362
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 23, 2024
Details:
IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for chronic weight management.
Lead Product(s): Mazdutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: IBI362
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2024
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Innovent Updates on Mazdutide GLORY-1 Study and Biomedicine Pipeline
Details : IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for chronic weight management.
Brand Name : IBI362
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 27, 2024
Details:
IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for Type 2 Diabetes
Lead Product(s): Mazdutide
Therapeutic Area: Endocrinology Brand Name: IBI362
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2024
Lead Product(s) : Mazdutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Innovent's Phase 3 Trial of Mazdutide in Type 2 Diabetes Meets Study Endpoints
Details : IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for Type 2 Diabetes
Brand Name : IBI362
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 08, 2024
Details:
IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for chronic weight management.
Lead Product(s): Mazdutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: IBI362
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Innovent's Mazdutide New Drug Application for Weight Management Accepted by China's NMPA
Details : IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for chronic weight management.
Brand Name : IBI362
Molecule Type : Peptide
Upfront Cash : Not Applicable
February 07, 2024
Details:
IBI362 (mazdutide) is a GLP-1R and GCGR dual agonist. It is under phase 3 clinical development for the treatment of adults with overweight or obesity.
Lead Product(s): Mazdutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: IBI362
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : Not Applicable
Deal Type : Not Applicable
Innovent’s Phase 3 Trial of Mazdutide Met Primary and Key Secondary Endpoints in China
Details : IBI362 (mazdutide) is a GLP-1R and GCGR dual agonist. It is under phase 3 clinical development for the treatment of adults with overweight or obesity.
Brand Name : IBI362
Molecule Type : Peptide
Upfront Cash : Not Applicable
January 08, 2024
Details:
IBI362 (mazdutide) is a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, which is under phase 3 clinical development for the treatment of obesity.
Lead Product(s): Mazdutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: IBI362
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 01, 2024
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : Not Applicable
Deal Type : Not Applicable
Innovent Doses First Participant in Phase 3 Study of Mazdutide in Adults with Obesity
Details : IBI362 (mazdutide) is a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, which is under phase 3 clinical development for the treatment of obesity.
Brand Name : IBI362
Molecule Type : Peptide
Upfront Cash : Not Applicable
January 01, 2024
Details:
IBI362 (Mazdutide) is a GLP-1R and GCGR dual agonist peptide, subcutaneous injection, which is being evaluated in phase 2 clinical trials for the treatment of Obesity.
Lead Product(s): Mazdutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: IBI362
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2023
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : IBI362 (Mazdutide) is a GLP-1R and GCGR dual agonist peptide, subcutaneous injection, which is being evaluated in phase 2 clinical trials for the treatment of Obesity.
Brand Name : IBI362
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 29, 2023
Details:
IBI362 (mazdutide) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes.
Lead Product(s): Mazdutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: IBI362
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Lead Product(s) : Mazdutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : IBI362 (mazdutide) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes.
Brand Name : IBI362
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 11, 2023
Details:
IBI362 (mazdutide) is a long-acting synthetic peptide, having GLP-1R and GCGR dual agonistic action, mimicking the effects of endogenous oxyntomodulin which promotes insulin secretion, lowering blood glucose and reducing body weight.
Lead Product(s): Mazdutide
Therapeutic Area: Endocrinology Brand Name: IBI362
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Lead Product(s) : Mazdutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : IBI362 (mazdutide) is a long-acting synthetic peptide, having GLP-1R and GCGR dual agonistic action, mimicking the effects of endogenous oxyntomodulin which promotes insulin secretion, lowering blood glucose and reducing body weight.
Brand Name : IBI362
Molecule Type : Peptide
Upfront Cash : Not Applicable
January 10, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?